Aerovate Historical Financial Ratios
| AVTE Stock | USD 2.62 0.04 1.55% |
Aerovate Therapeutics is presently reporting on over 83 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 5.14 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Aerovate Therapeutics financial condition quickly.
Aerovate |
About Aerovate Financial Ratios Analysis
Aerovate TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aerovate Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aerovate financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aerovate Therapeutics history.
Aerovate Therapeutics Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Aerovate Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aerovate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.At present, Aerovate Therapeutics' PB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 0.04, whereas Free Cash Flow Yield is forecasted to decline to (0.12).
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 16.9 | 7.04 | 6.34 | 6.02 | Net Debt To EBITDA | 0.4 | 0.28 | 0.32 | 0.31 |
Aerovate Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Aerovate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aerovate Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | (41.76) | 1.67 | 5.66 | 5.44 | 4.9 | 5.14 | |
| Book Value Per Share | (0.55) | 7.06 | 5.18 | 4.16 | 3.74 | 2.51 | |
| Free Cash Flow Yield | (0.0141) | (0.0958) | (0.0548) | (0.0955) | (0.11) | (0.12) | |
| Operating Cash Flow Per Share | (0.32) | (1.12) | (1.6) | (2.16) | (2.48) | (2.36) | |
| Pb Ratio | (41.76) | 1.67 | 5.66 | 5.44 | 4.9 | 5.14 | |
| Free Cash Flow Per Share | (0.32) | (1.13) | (1.61) | (2.16) | (2.49) | (2.36) | |
| Roic | (2.84) | (0.13) | (0.42) | (0.74) | (0.67) | (0.7) | |
| Net Income Per Share | (0.37) | (0.94) | (2.1) | (2.87) | (3.3) | (3.13) | |
| Cash Per Share | 0.19 | 6.86 | 5.28 | 4.65 | 4.18 | 2.74 | |
| Pocfratio | (70.91) | (10.5) | (18.33) | (10.49) | (9.45) | (9.92) | |
| Pfcf Ratio | (70.91) | (10.44) | (18.24) | (10.47) | (9.42) | (9.89) | |
| Income Quality | 0.82 | 1.19 | 0.76 | 0.75 | 0.86 | 0.96 | |
| Roe | 0.68 | (0.13) | (0.41) | (0.69) | (0.79) | (0.75) | |
| Ev To Operating Cash Flow | (70.33) | (8.55) | (17.78) | (10.09) | (9.08) | (9.54) | |
| Pe Ratio | (61.65) | (12.53) | (13.92) | (7.89) | (7.1) | (7.46) | |
| Return On Tangible Assets | (1.92) | (0.13) | (0.38) | (0.59) | (0.53) | (0.56) | |
| Ev To Free Cash Flow | (70.33) | (8.49) | (17.7) | (10.07) | (9.06) | (9.51) | |
| Earnings Yield | (0.0162) | (0.0798) | (0.0718) | (0.13) | (0.15) | (0.14) | |
| Current Ratio | 2.64 | 68.37 | 16.9 | 7.04 | 6.34 | 6.02 | |
| Tangible Book Value Per Share | (0.55) | 7.06 | 5.18 | 4.16 | 3.74 | 2.51 | |
| Graham Number | 2.13 | 12.23 | 15.66 | 16.38 | 14.74 | 7.54 | |
| Shareholders Equity Per Share | (0.55) | 7.06 | 5.18 | 4.16 | 3.74 | 2.51 | |
| Graham Net Net | (0.55) | 6.74 | 4.93 | 3.97 | 3.57 | 2.39 | |
| Interest Debt Per Share | 0.003072 | 0.0262 | 0.0445 | 0.0256 | 0.0295 | 0.0444 | |
| Enterprise Value Over E B I T D A | (62.19) | (10.18) | (13.09) | (7.05) | (8.1) | (7.7) | |
| Price Earnings Ratio | (61.65) | (12.53) | (13.92) | (7.89) | (7.1) | (7.46) | |
| Price Book Value Ratio | (41.76) | 1.67 | 5.66 | 5.44 | 4.9 | 5.14 | |
| Price To Operating Cash Flows Ratio | (70.91) | (10.5) | (18.33) | (10.49) | (9.45) | (9.92) | |
| Price To Free Cash Flows Ratio | (70.91) | (10.44) | (18.24) | (10.47) | (9.42) | (9.89) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.